Actin Antibody

If you've had months of bloating, loose stools, or a celiac scare, you may be wondering whether your intestinal lining is damaged. Stool actin antibody testing has a preliminary research link to celiac disease, but its ability to answer that question for an individual remains unproven. It belongs in the research and exploratory tier of testing.

What This Test Picks Up

Actin is a protein that helps cells keep their shape and move. It's found throughout your body, including in intestinal lining cells. Anti-actin antibodies bind to this protein, but detecting them doesn't establish where the immune response began or whether the antibodies themselves are causing damage.

This test measures antibody reactivity in stool by immunoassay and reports an index. An immunoassay detects binding between an antibody and its target. An index is a score on the assay's own scale; it isn't a universal antibody concentration or a measure of how much intestine is injured.

The catalog doesn't specify the antibody class or the form of actin used as the target. IgA and IgG are different antibody classes, and F-actin is the filament form of actin. Evidence about a particular class or target cannot automatically be applied to this result. Finding antibodies in stool also doesn't prove that they were produced locally in the gut.

What the Stool Research Shows

A small study measured IgA anti-actin antibodies in liquid extracted from stool. Levels were higher in 25 people with celiac disease than in 12 healthy volunteers. The researchers used an enzyme-linked immunoassay, commonly called ELISA. This is direct human evidence that fecal anti-actin antibodies can be associated with celiac disease.

That study compared groups. It did not establish this catalog test's accuracy in people with unexplained symptoms, its ability to grade intestinal injury, or its usefulness for following recovery. Its IgA-specific research assay cannot be assumed equivalent to an unspecified antibody-class immunoassay reported as an index.

What Blood Studies Add

Several studies measured IgA anti-actin antibodies in serum obtained from blood draws. Some found that these antibodies were more common with severe flattening of the intestinal villi. Villi are small projections in the intestinal lining that help absorb nutrients, and celiac disease can damage them.

The results depended on the assay and the population. One microscopy-based serum study detected anti-actin IgA in about a quarter of people with celiac disease and in none of its controls. A pediatric study found that the antibodies could be absent despite severe intestinal damage. A later study using a different serum immunoassay found no association between anti-actin antibodies and flattened villi. These findings don't establish how reliably this stool test detects or excludes disease.

Current celiac guidelines use validated blood antibody tests and, in many cases, intestinal biopsy. They do not include stool anti-actin testing as an established diagnostic add-on. A positive stool result cannot confirm celiac disease, and a negative one cannot exclude it.

Crohn's Disease and Colitis

An older study of 60 people with Crohn's disease found serum actin antibodies in several antibody classes. IgG actin antibody levels were highest when Crohn's affected only the colon. This was an association in blood; it did not show that colon inflammation causes a particular stool antibody reading.

The study provides no validated way to use this stool index to diagnose Crohn's disease, distinguish it from ulcerative colitis, or monitor either condition. It also doesn't establish that an unexpected stool result is caused by an existing bowel disease.

Why Autoimmune Hepatitis Research Is Different

Serum F-actin IgG testing has an established supporting role in evaluating autoimmune hepatitis. That diagnosis depends on the combination of liver blood tests, serum antibodies, exclusion of other causes, and usually a liver biopsy. F-actin antibodies alone are not diagnostic.

In one serum study, F-actin IgG was detected in a quarter of samples with laboratory evidence of viral hepatitis, mostly at low levels. An older study in people already diagnosed with autoimmune hepatitis linked serum actin antibodies with worse liver outcomes. Neither finding provides a diagnosis or a liver-risk estimate from this stool index.

When Results Can Be Misleading

The main problem is applying findings from a different test to this one. Even serum F-actin immunoassays and microscope-based smooth muscle antibody tests can disagree. A 2026 serum comparison found only moderate agreement for one smooth muscle staining pattern. It did not study stool.

• Different targets or antibody classes: a stool actin result, a serum F-actin IgG result, and a smooth muscle antibody result are different measurements.
• Different assay scales: index values from different laboratories or kits are not directly comparable. A doubled index has no established relationship to a doubling of tissue injury.
• Immunoassay interference: binding to unintended targets or interference from substances in the sample can affect antibody assays. The relevant interferences and their size must be established for this stool method; serum interference data cannot supply those answers.
• Sample preparation and stability: extraction, dilution, storage, and stool composition need assay-specific validation. The cited clinical studies do not establish a predictable correction for watery or hard stool.
• Unvalidated interpretation: a laboratory flag does not establish celiac disease, intestinal permeability, or an autoimmune attack on your gut.

What a Trend Can Mean

A series of results may document changes in the assay signal, but there is no established link between a change in this stool index and healing, a flare, or future disease risk. Using the same laboratory reduces one source of variation; it doesn't turn the result into a validated measure of gut health.